Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

AM Menzies, RN Amaria, EA Rozeman, AC Huang… - Nature medicine, 2021 - nature.com
The association among pathological response, recurrence-free survival (RFS) and overall
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we …
被引用次数：290 相关文章

[引用][C] Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC …

AM Menzies, RN Amaria, EA Rozeman, AC Huang… - Nature Medicine, 2021 - cir.nii.ac.jp
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis
from the International Neoadjuvant Melanoma Consortium (INMC) | CiNii Research CiNii 国立 …

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

AM Menzies, RN Amaria, EA Rozeman, AC Huang… - paper.sciencenet.cn
The association among pathological response, recurrence-free survival (RFS) and overall
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we …

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

AM Menzies, RN Amaria, EA Rozeman, AC Huang… - Nature …, 2021 - europepmc.org
The association among pathological response, recurrence-free survival (RFS) and overall
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we …

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

AM Menzies, RN Amaria, EA Rozeman… - Nature …, 2021 - pubmed.ncbi.nlm.nih.gov
The association among pathological response, recurrence-free survival (RFS) and overall
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we …

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

AM Menzies, RN Amaria… - Nature …, 2021 - mdanderson.elsevierpure.com
The association among pathological response, recurrence-free survival (RFS) and overall
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we …

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

AM Menzies, RN Amaria, EA Rozeman, AC Huang… - Nature Medicine, 2021 - go.gale.com
The association among pathological response, recurrence-free survival (RFS) and overall
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we …

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

AM Menzies, RN Amaria, EA Rozeman, AC Huang… - paper.sciencenet.cn
The association among pathological response, recurrence-free survival (RFS) and overall
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we …